LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

Search

Simulations Plus Inc

Avatud

SektorTervishoid

16.1 4.95

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.27

Max

16.12

Põhinäitajad

By Trading Economics

Sissetulek

-70M

-67M

Müük

-2.1M

20M

P/E

Sektori keskmine

48.528

35.664

Dividenditootlus

0.48

Kasumimarginaal

-330.585

Töötajad

243

EBITDA

-79M

-74M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+63.64% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

3.12%

Järgmine tulemuste avaldamine

22. okt 2025

Turustatistika

By TradingEconomics

Turukapital

-48M

303M

Eelmine avamishind

11.15

Eelmine sulgemishind

16.1

Uudiste sentiment

By Acuity

50%

50%

185 / 371 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. sept 2025, 17:03 UTC

Suurimad hinnamuutused turgudel

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. sept 2025, 16:49 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

GD Culture Shares Drop After Deal for Pallas Capital

16. sept 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. sept 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. sept 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. sept 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. sept 2025, 21:10 UTC

Omandamised, ülevõtmised, äriostud

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. sept 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. sept 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 20:25 UTC

Tulu

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. sept 2025, 20:24 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. sept 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. sept 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. sept 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. sept 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. sept 2025, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. sept 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. sept 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. sept 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. sept 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. sept 2025, 16:53 UTC

Tulu

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. sept 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 16:15 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Energy Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. sept 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. sept 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

63.64% tõus

12 kuu keskmine prognoos

Keskmine 25.25 USD  63.64%

Kõrge 31 USD

Madal 20 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

185 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat